Heron Therapeutics Inc (NASDAQ:HRTX) Expected to Announce Quarterly Sales of $33.63 Million
Equities analysts predict that Heron Therapeutics Inc (NASDAQ:HRTX) will announce sales of $33.63 million for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Heron Therapeutics’ earnings. The highest sales estimate is $37.20 million and the lowest is $30.00 million. Heron Therapeutics reported sales of $19.79 million during the same quarter last year, which indicates a positive year-over-year growth rate of 69.9%. The firm is expected to announce its next quarterly earnings report on Wednesday, November 6th.
On average, analysts expect that Heron Therapeutics will report full-year sales of $130.42 million for the current year, with estimates ranging from $124.00 million to $139.30 million. For the next year, analysts expect that the business will report sales of $197.38 million, with estimates ranging from $150.00 million to $253.70 million. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Heron Therapeutics.
Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.02. Heron Therapeutics had a negative return on equity of 56.89% and a negative net margin of 172.07%. The business had revenue of $36.66 million for the quarter, compared to the consensus estimate of $31.04 million.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FMR LLC raised its position in shares of Heron Therapeutics by 5.5% in the first quarter. FMR LLC now owns 8,473,847 shares of the biotechnology company’s stock valued at $207,101,000 after buying an additional 439,044 shares in the last quarter. Vanguard Group Inc. raised its position in Heron Therapeutics by 5.2% during the second quarter. Vanguard Group Inc. now owns 6,744,858 shares of the biotechnology company’s stock valued at $125,387,000 after purchasing an additional 330,351 shares in the last quarter. BlackRock Inc. raised its position in Heron Therapeutics by 0.9% during the second quarter. BlackRock Inc. now owns 4,901,392 shares of the biotechnology company’s stock valued at $91,116,000 after purchasing an additional 42,657 shares in the last quarter. Clearbridge Investments LLC raised its position in Heron Therapeutics by 153.4% during the first quarter. Clearbridge Investments LLC now owns 2,180,577 shares of the biotechnology company’s stock valued at $53,293,000 after purchasing an additional 1,320,025 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in Heron Therapeutics by 60.2% during the second quarter. JPMorgan Chase & Co. now owns 1,425,517 shares of the biotechnology company’s stock valued at $26,274,000 after purchasing an additional 535,821 shares in the last quarter.
Shares of HRTX stock traded down $0.23 on Monday, reaching $20.51. 846,271 shares of the company’s stock traded hands, compared to its average volume of 947,332. Heron Therapeutics has a 12-month low of $15.68 and a 12-month high of $35.52. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.70 and a current ratio of 4.01. The company has a market capitalization of $1.64 billion, a P/E ratio of -8.41 and a beta of 1.47. The business’s 50 day moving average price is $17.75 and its two-hundred day moving average price is $20.27.
About Heron Therapeutics
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
See Also: Swap
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.